Aim:Meningiomas are mostly benign intracranial tumors with high angiogenic potential. Although the most common treatment methods include total resection and radiosurgery, these may be insufficient for certain World Health Organization grades of the disease or in case of recurrence. Currently, there are no systematic drug treatment methodologies that can be used in such cases. Meningiomas have high vascularization potential, and antiangiogenic drug trials that investigate the effects of these drugs on meningioma tumorigenesis are of importance as they can potentially improve patient well-being and survival.Material and Methods:In this study, in silico analysis of angiogenesis-related gene expression was carried out using previously reported datasets. Messenger ribonucleic acid expressions of VEGFA, VEGFB, PDGFRA, and PDGFRB genes were obtained from two different meningioma transcriptome datasets. The effect of antiangiogenic drugs, bevacizumab and imatinib, on meningioma-induced vascularization was assessed by using rat corneal angiogenesis assay (CAA).Results:Bevacizumab and imatinib both significantly reduced meningioma-induced neovascularization in the CAA model.Conclusion:The angiogenic characteristics of meningiomas may be suppressed by using antiangiogenic drugs to prevent neovascularization, thus improving prognosis.